Home > Resources > Company Profiles > Invitrogen Corporation

Invitrogen Corporation (IVGN)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Gregory T. Lucier , CEO/Chairman of the Board/Director

www.invitrogen.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A developer, manufacturer and marketer of research tools in reagent, kit and high-throughput applications forms to customers engaged in life sciences research, drug discovery, diagnostics and the commercial manufacture of biological products.

News Feeds

Invitrogen raises 2009 guidance on buyout savings AP
Oct 09 2008
Invitrogen says outside advisers endorse buyout AP
Oct 07 2008
Invitrogen, Applied Biosystems new structure AP
Sep 18 2008
Invitrogen nears funding completion for buyout AP
Sep 17 2008

Press Releases

Invitrogen Announces Completion of Detailed Integration Plans Relating to Applied Biosystems Combination Oct-09-2008, 09:15AM EDT
Protein Linked to Spinal Muscular Atrophy Identified Oct-08-2008, 04:03PM EDT
Invitrogen Redesigns GIBCO(R) Bottle to Improve Form and Function Oct-08-2008, 08:03AM EDT
Invitrogen Files Merger Notification With European Commission Oct-07-2008, 09:00AM EDT
Applied Biosystems, Amaxa, and Invitrogen Lead Attractive Gene Silencing Market - Revealed in New Life Science Dashboard(TM) Market Research Report Oct-06-2008, 10:45AM EDT

News From Around the Web

News

Invitrogen Hits Multi-Year Low (RTTNews)

Oct 10 2008
Invitrogen Launches Countess(TM) (Genetic Engineering News)

Oct 10 2008
InvitrogenLaunches Countess(TM) (MarketWatch)

Oct 10 2008
Invitrogen Joins EPA's Climate Leaders Program (Genetic Engineering News)

Oct 09 2008
Invitrogen raises 2009 guidance on buyout savings (Boston Globe)

Oct 09 2008
UPDATE 1-Invitrogen raises EPS view, says merger on track (Reuters)

Oct 09 2008
Invitrogen Announces Completion of Detailed Integration Plans Relating to Applied Biosystems Combination (PharmaLive)

Oct 09 2008
Invitrogen Congratulates Winners of Nobel Prize in Chemistry (PharmaLive)

Oct 09 2008
Protein Linked to Spinal Muscular Atrophy Identified (PharmaLive)

Oct 09 2008

Employees

Number of Employees: 4,300

Revenue per Employee: $263,723

Top Executives

David F. Hoffmeister, CFO/Divisional Senior VP

Dr. Claude D. Benchimol, Ph.D., Divisional Senior VP

John A. Cottingham, Senior VP/Secretary/General Counsel

Kelli A. Richard, Chief Accounting Officer/Vice President, Divisional

Nicolas M. Barthelemy, Divisional Senior VP

John (Kip) Miller, Divisional Senior VP

Dr. Paul Grossman, Senior VP, Divisional

John D. Thompson, Vice President, Divisional

Bernd Brust, Divisional Senior VP

Karen S. Gibson, Chief Information Officer

Dr. Peter M. Leddy, Divisional Senior VP

Board of Directors

Ronald A. Matricaria, Director

Donald W. Grimm, Director

Balakrishnan S. Iyer, Director

Dr. David C. U'Prichard, Ph.D., Director

Dr.W. Ann Reynolds, Director

John A. Cottingham, Senior VP/Secretary/General Counsel

Raymond V. Dittamore, Director

Bradley G. Lorimier, Director

Dr. Per A. Peterson, Ph.D., Director

Dr. Jay M. Short, Ph.D., Director

Financials

Quarterly

Annual

Income Statement	07/2008	04/2008	02/2008	10/2007
Sales	142.68 Mil.	114.56 Mil.	-7.34 Mil.	104.08 Mil.
Gross Operating Profit	225.11 Mil.	235.66 Mil.	343.79 Mil.	210.88 Mil.
Operating Income before D & A (EBITDA)	76.41 Mil.	228.24 Mil.	205.73 Mil.	78.02 Mil.
Total Income Before Interest Expenses (EBIT)	79.99 Mil.	238.46 Mil.	62.39 Mil.	48.89 Mil.
Total Net Income	53.22 Mil.	59.73 Mil.	41.05 Mil.	31 Mil.
Basic EPS, Total	0.58	1.29	0.88	0.67
Diluted EPS, Total	0.55	1.22	0.83	0.64

BALANCE STATEMENT	07/2008	04/2008	02/2008	10/2007
Cash and Equivalents	646.08 Mil.	NA	671.29 Mil.	594.28 Mil.
Total Assets	1.13 Bil.	NA	1.09 Bil.	1.06 Bil.
Total Liabilities	231.61 Mil.	NA	234.41 Mil.	209.09 Mil.
Total Capitalization	3.03 Bil.	NA	1.77 Bil.	2.87 Bil.

Cash Flow	07/2008	04/2008	02/2008	10/2007
Net Cash From Continuing Operations	NA	NA	245.2 Mil.	225.01 Mil.
Net Cash From Investing Activities	NA	NA	126.79 Mil.	115.1 Mil.
Net Cash From Financing Activities	NA	NA	-143.24 Mil.	-118.98 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	239.25 Mil.	228.04 Mil.

Income Statement	2008	2007	2006	2005
Sales	387.43 Mil.	469.62 Mil.	439.7 Mil.	359.49 Mil.
Gross Operating Profit	894.32 Mil.	793.86 Mil.	758.75 Mil.	664.36 Mil.
Operating Income before D & A (EBITDA)	362.38 Mil.	283.51 Mil.	316.05 Mil.	299.92 Mil.
Total Income Before Interest Expenses (EBIT)	206.61 Mil.	-130.38 Mil.	208.03 Mil.	153.58 Mil.
Total Net Income	143.19 Mil.	-191.05 Mil.	132.05 Mil.	88.82 Mil.
Basic EPS, Total	3.07	-3.72	2.53	1.72
Diluted EPS, Total	2.95	-3.72	2.53	1.63

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	671.29 Mil.	366.89 Mil.	435.23 Mil.	198.4 Mil.
Total Assets	1.09 Bil.	797.86 Mil.	1.15 Bil.	1.33 Bil.
Total Liabilities	234.41 Mil.	247.63 Mil.	511.58 Mil.	196.18 Mil.
Total Capitalization	1.77 Bil.	2.78 Bil.	3.19 Bil.	3.21 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	245.2 Mil.	235.06 Mil.	309.34 Mil.	252.72 Mil.
Net Cash From Investing Activities	126.79 Mil.	229.82 Mil.	-157.64 Mil.	-689.48 Mil.
Net Cash From Financing Activities	-143.24 Mil.	-549.15 Mil.	104.88 Mil.	232.88 Mil.
Net Change in Cash & Cash Equivalents	239.25 Mil.	-68.34 Mil.	236.83 Mil.	-198.62 Mil.

Invitrogen Corporation (IVGN)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request